Hadean Ventures is a European life science venture capital fund manager based in Oslo, Norway, with over EUR 230 million in assets under management. The firm invests in life science and healthcare companies developing breakthrough innovative solutions across Europe, with a particular focus on the Nordic region.
84% of their portfolio is in Biotech & Life Sciences. Deal activity increased 50% year-over-year (3 deals in the last 12 months). Their most common stage is series-a (42% of deals). Average disclosed round size is $78.0M (across 8 rounds with reported amounts).
Portfolio
23
Fund Size
$158M
Top Stage
Series A
Last 12 Mo
3
Team
Ingrid Teigland Akay
Managing Partner
Reinhard Krickl
Venture Partner
Roger Franklin
Partner
Yun Yang
Investment Associate
Portfolio Breakdown
Stage Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Step Pharma | Series C | — | Oct 2025 |
 Arthex Biotech | Series B | $87M | Sep 2025 |
| AARTHEX BIOTECH S.L. | Series B | $87M | Sep 2025 |
 Actithera | Series A | $75.5M | Jul 2025 |
 Neuro Event Labs Oy | Series A | — | Feb 2025 |
 Contineum Therapeutics | Series B | $30M | Jan 2025 |
 Gesynta Pharma | Series B | — | Jan 2025 |
 Scirhom | Series A | — | Jul 2024 |
| Scirhom | Unknown | — | Jan 2024 |
 Complement Therapeutics | Series A | — | Apr 2023 |
| CComplement | Series A | — | Apr 2023 |
 TargED Biopharmaceuticals B.V. | Series A | — | Feb 2022 |
| TTarged Biopharmaceuticals | Series A | — | Jan 2022 |
| TargED Biopharmaceuticals B.V. | Series A | — | Jan 2022 |
| EEmergence Therapeutics | Series A | — | Dec 2021 |
 Cardior | Series B | — | Aug 2021 |
 Pipeline Therapeutics | Series C | $110M | Jan 2021 |
| Neuro Event Labs Oy | Series A | — | Apr 2020 |
| TThemis Bioscience | Unknown | — | Sep 2019 |
| TThemis Bioscience | Series D | $95M | Jan 2019 |
 Galecto | Series C | — | Oct 2018 |
| GGalecto Biotech | Series C | — | Oct 2018 |
 Nisonic | Unknown | — | Jul 2018 |
| Actithera | Series A | $75.5M | — |
| Cardior | Series B | — | — |
Top Co-Investors
Last updated: 27 September 2026